<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623180</url>
  </required_header>
  <id_info>
    <org_study_id>12EU01</org_study_id>
    <nct_id>NCT01623180</nct_id>
  </id_info>
  <brief_title>A Randomized Clinical Evaluation of the BioFreedom™ Stent</brief_title>
  <acronym>Leaders Free</acronym>
  <official_title>A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is
      non-inferior to a bare metal stent at one year as measured by the composite safety endpoint
      of cardiovascular death, myocardial infarction and definite/probable stent thrombosis, and
      that its efficacy is superior to a bare metal stent as measured by clinically driven TLR at
      one year.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Safety Endpoint</measure>
    <time_frame>one year</time_frame>
    <description>Composite of cardiac death, myocardial infarction and definite/probable stent thrombosis at one year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>one year</time_frame>
    <description>The incidence of clinically driven target lesion revascularization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2456</enrollment>
  <condition>Stable Angina</condition>
  <condition>Ischemic Heart Disease Silent</condition>
  <condition>ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction</condition>
  <condition>In-stent Coronary Artery Restenosis</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>BioFreedom™ Drug Coated Stent (DCS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gazelle™ Bare Metal Coronary Stent (BMS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofreedom™ Drug Coated Stent (DCS)</intervention_name>
    <description>Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT</description>
    <arm_group_label>BioFreedom™ Drug Coated Stent (DCS)</arm_group_label>
    <other_name>Drug coated stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gazelle™ Bare Metal Coronary Stent (BMS)</intervention_name>
    <description>Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT</description>
    <arm_group_label>Gazelle™ Bare Metal Coronary Stent (BMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any indication for PCI-S in patients deemed at high risk for bleeding and candidates
             for 1 month DAPT. This includes candidates with stable angina, silent ischemia, ACS
             (STEMI and non-STEMI), non-native lesions and in-stent restenosis. Patients must
             provide written informed consent.

        Exclusion Criteria:

          1. Pregnancy

          2. Patients expected not to comply with 1 month DAPT

          3. Patients requiring a planned staged PCI procedure more than one week after the index
             procedure

          4. Procedure planned to require non-study stents, or stand alone POBA or stand-alone
             atherectomy

          5. Active bleeding at the time of inclusion

          6. Reference vessel diameter &lt;2.25 - &gt;4.0mm

          7. Cardiogenic shock

          8. Compliance with long-term single anti-platelet therapy unlikely

          9. A known hypersensitivity or contraindication to aspirin, clopidogrel (or prasugrel, or
             ticagrelor if applicable), stainless steel, Biolimus A9 or a sensitivity to contrast
             media, which cannot be adequately pre-medicated.

         10. Participation in another clinical trial (12 months after index procedure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Tour</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Tour</name>
      <address>
        <city>Meyrin</city>
        <zip>1217</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DES</keyword>
  <keyword>coronary stent</keyword>
  <keyword>bare metal stent</keyword>
  <keyword>high bleeding</keyword>
  <keyword>MI</keyword>
  <keyword>angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

